The objective of this study was to assess the pharmacodynamics of ipragliflozin in T2DM patients with impaired renal function ... Because SGLT2 inhibitors act on the kidney, and the amount ...

While SGLT2 inhibitors have been included in international treatment guidelines for people with diabetes and CKD since 2018, only around 7% of these patients in the US are receiving these ...

Renal glucose reabsorption involves two transporter families: the SGLTs secondary active Na + /D-glucose co-transporters located at the brush border of tubular cells (SGLT2 and SGLT1) and the ...

AstraZeneca is already seeing sales rocket for its SGLT2 inhibitor Farxiga in heart failure, and is expected to gather even more momentum after claiming FDA approval in chronic kidney disease (CKD).

and Eli Lilly/Boehringer Ingelheim's Jardiance (empagliflozin), two SGLT2 inhibitors which showed stronger effects on CKD in their phase 3 trials. Bayer's position is that Kerendia is not so much ...

One in ten adults suffer from chronic kidney disease (CKD), a condition characterized ... behind low therapy persistence, such as with SGLT2-i, and finding ways to improve adherence are critical ...

Starting SGLT2 inhibitors led to a lower risk of ... Diabetes is a “major contributor to the rising global burden of chronic kidney disease associated with significant morbidity, high mortality ...

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, CVD and overall mortality.